Gain Therapeutics (Gain Therapeutics) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gain Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gain Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.37.

Gain Therapeutics Accounts Receivable Historical Data

The historical data trend for Gain Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics Accounts Receivable Chart

Gain Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.01

Gain Therapeutics Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial														-	-	-	-	-

Gain Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Gain Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Gain Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gain Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Gain Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(12.661	+	0.75 * 0	+	0.5 * 0	-	5.935
-	0	-	0)	/	18.0412
=	0.37

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Gain Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gain Therapeutics (Gain Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814

Website

https://www.gaintherapeutics.com

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.

Executives

Matthias Alder	officer: Chief Operating Officer	C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne	officer: Chief Financial Officer	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta	officer: Principal Accounting Officer	C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese	officer: Chief Financial Officer	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md	director
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto	officer: President and General Manager	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814